卡瑞利珠单抗治疗经治晚期肝细胞癌的II期随机试验
这项在中国13个中心开展的开放标签、平行组、随机II期试验纳入220例经治晚期肝细胞癌患者,随机接受卡瑞利珠单抗3 mg/kg每2周或每3周一次。
要点
- ≥3级治疗相关不良事件发生率为22%,最常见为AST升高和中性粒细胞减少。
- 卡瑞利珠单抗在经治中国晚期肝细胞癌患者中显示抗肿瘤活性且毒性可控。
核心结论
- 卡瑞利珠单抗在经治中国晚期肝细胞癌患者中显示抗肿瘤活性,毒性可控,可能成为新的治疗选择。
研究设计与样本
- 多中心、开放标签、平行组、随机II期试验,在中国13个研究中心开展。
- 筛查303例,随机分配220例合格患者,其中217例接受卡瑞利珠单抗治疗(每2周109例,每3周108例)。
- 入组标准为18岁及以上、组织学或细胞学诊断的晚期肝细胞癌、既往系统治疗进展或不耐受、ECOG评分0-1。
- 主要终点为盲法独立中心评审的客观缓解和6个月总生存,在至少接受一剂研究治疗的全部随机患者中分析。
主要发现
- 47例(22%)发生≥3级治疗相关不良事件,最常见为天冬氨酸氨基转移酶升高(10例[5%])和中性粒细胞计数降低(7例[3%])。
- 2例死亡被研究者判定可能与治疗相关(一例肝功能不全,一例多器官衰竭)。
临床怎么用
- 卡瑞利珠单抗3 mg/kg每2周或每3周静脉给药可作为经治晚期肝细胞癌患者的潜在治疗选择。
- 治疗期间需监测肝功能(尤其AST)和血常规(中性粒细胞计数)等不良事件。
局限性
- 本研究为II期单臂随机对照试验,样本量有限,结论需进一步III期试验验证。
- 研究仅纳入中国患者,结果外推至其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Blocking the interaction between PD-1 and its ligands is a promising treatment strategy for advanced hepatocellular carcinoma. This study aimed to assess the antitumour activity and safety of the anti-PD-1 inhibitor camrelizumab in pretreated patients with advanced hepatocellular carcinoma. METHODS: This is a multicentre, open-label, parallel-group, randomised, phase 2 trial done at 13 study sites in China. Eligible patients were aged 18 years and older with a histological or cytological diagnosis of advanced hepatocellular carcinoma, had progressed on or were intolerant to previous systemic treatment, and had an Eastern Cooperative Oncology Group performance score of 0-1. Patients were randomly assigned (1:1) to receive camrelizumab 3 mg/kg intravenously every 2 or 3 weeks, via a centralised interactive web-response system using block randomisation (block size of four). The primary endpoints were objective response (per blinded independent central review) and 6-month overall survival, in all randomly assigned patients who had at least one dose of study treatment. Safety was analysed in all treated patients. This study is registered with ClinicalTrials.gov, number NCT02989922, and follow-up is ongoing, but enrolment is closed. FINDINGS: Between Nov 15, 2016, and Nov 16, 2017, 303 patients were screened for eligibility, of whom 220 eligible patients were randomly assigned and among whom 217 received camrelizumab (109 patients were given treatment every 2 weeks and 108 every 3 weeks). Median follow-up was 12·5 months (IQR 5·7-15·5). Objective response was reported in 32 (14·7%; 95% CI 10·3-20·2) of 217 patients. The overall survival probability at 6 months was 74·4% (95% CI 68·0-79·7)]. Grade 3 or 4 treatment-related adverse events occurred in 47 (22%) of 217 patients; the most common were increased aspartate aminotransferase (ten [5%]) and decreased neutrophil count (seven [3%]). Two deaths were judged by the investigators to be potentially treatment-related (one due to liver dysfunction and one due to multiple organ failure). INTERPRETATION: Camrelizumab showed antitumour activity in pretreated Chinese patients with advanced hepatocellular carcinoma, with manageable toxicities, and might represent a new treatment option for these patients. FUNDING: Jiangsu Hengrui Medicine.
引用
- Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020. PMID: 32112738. doi:10.1016/S1470-2045(20)30011-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。